Video

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

Author(s):

Michael Atkins, MD,Evan Lipson, MD

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Related Videos
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Radiomic Biomarkers in Uveal Melanoma Metastases | Image Credit: © ReisMedia - stock.adobe.com
November 7th 2024

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27